Background and Objective: Scientific evidence suggests a relationship between regular consumption of sugar-sweetened beverages (SSB) and the increased prevalence of type 2 diabetes mellitus (DM2) and ischemic heart disease (IHD). Although this association has been well reported in the scientific literature, there are few studies that estimate the impact of this risk factor on the costs of health services, which subsidize the treatment of these diseases. Thus, this study Aims to estimate the financial costs for the treatment of DM2 e IHD attributed to the consumption of  SSB in the Brazilian Unified Health System (SUS) in 2019. Methods: This is a descriptive ecological study using secondary and public domain data. The costs of DM2 e IHD  attributable to the consumption of SSBs were estimated from the Population Attributable Fraction (PAF), extracted from the Global Burden of Disease (GBD) 2019 study, whose parameters are the prevalence estimates of SSB consumption in the population, the relative risks related to the risk-outcome pairs, and the minimum risk  exposure level. The FAP was multiplied to the total spent for treatment of DM2 and IHD in secondary and tertiary health care  according to the Brazilian ambulatory and hospital healthcare information systems. The analysis were stratified by sex, age groups. Results: In 2019, in Brazil, the treatment of attributed to the consumption of sugar-sweetened beverages costed US$14,116240.55. These costs were higher in males (US$8,469265.14) compared to females (US$5,646975.42) and greater for older age groups (over 60 years). Conclusions: This study revealed the high economic impact of high and medium complexity treatment of DM2 e IHD attributed to the consumption of SSBs in Brazil. The results demonstrated the urgency and the need for the expansion of public policies to reduce the consumption of SSBs in Brazil.